Kemadrin (Procyclidine Hydrochloride)

Procyclidine works by competitively blocking muscarinic acetylcholine receptors in the brain. This antagonism reduces excessive cholinergic activity, helping to restore the normal balance between dopamine and acetylcholine that is disrupted in Parkinsonian and drug‑induced movement disorders, thereby improving motor symptoms.

The specific dose of Kemadrin is determined by the prescribing clinician based on the patient’s condition, age, renal and hepatic function, and response to therapy. Dosage regimens are individualized and should follow the prescriber’s instructions and local prescribing guidelines.

The safety of Kemadrin in pregnancy and lactation has not been established, and the pregnancy category is listed as unknown. Healthcare providers should weigh potential benefits against possible risks and consider alternative therapies when treating pregnant or nursing individuals.

To request Kemadrin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Kemadrin (procyclidine) is similar to other anticholinergics like benztropine and trihexyphenidyl in its mechanism of blocking muscarinic receptors. Differences may include potency, duration of action, and side‑effect profiles. Choice of agent often depends on patient tolerance, specific symptom control, and clinician preference.

Kemadrin should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original packaging, protect them from moisture, and store away from direct sunlight to maintain stability and potency.

Kemadrin is administered orally, typically as a tablet taken with or without food as directed by the prescriber. Patients should follow the dosing schedule provided by their healthcare professional and avoid crushing or chewing the tablet unless instructed otherwise.

Serious risks include confusion, hallucinations, severe tachycardia, allergic reactions such as rash or anaphylaxis, and rare occurrences of neuroleptic malignant syndrome. Patients should seek immediate medical attention if they experience any of these severe symptoms.

Kemadrin is contraindicated in individuals with known hypersensitivity to procyclidine or any component of the formulation, as well as in patients with uncontrolled narrow‑angle glaucoma, severe urinary retention, or those taking other potent anticholinergic drugs that could lead to additive toxicity.